241 related articles for article (PubMed ID: 28839145)
1. DACT1 Overexpression in type I ovarian cancer inhibits malignant expansion and cis-platinum resistance by modulating canonical Wnt signalling and autophagy.
Li RN; Liu B; Li XM; Hou LS; Mu XL; Wang H; Linghu H
Sci Rep; 2017 Aug; 7(1):9285. PubMed ID: 28839145
[TBL] [Abstract][Full Text] [Related]
2. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic function of DACT1 in colon cancer through the regulation of β-catenin.
Yuan G; Wang C; Ma C; Chen N; Tian Q; Zhang T; Fu W
PLoS One; 2012; 7(3):e34004. PubMed ID: 22470507
[TBL] [Abstract][Full Text] [Related]
4. DACT1, an antagonist to Wnt/β-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer.
Yin X; Xiang T; Li L; Su X; Shu X; Luo X; Huang J; Yuan Y; Peng W; Oberst M; Kelly K; Ren G; Tao Q
Breast Cancer Res; 2013 Mar; 15(2):R23. PubMed ID: 23497530
[TBL] [Abstract][Full Text] [Related]
5. Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells.
Barghout SH; Zepeda N; Xu Z; Steed H; Lee CH; Fu Y
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):173-8. PubMed ID: 26522223
[TBL] [Abstract][Full Text] [Related]
6. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
7. Dact1, a nutritionally regulated preadipocyte gene, controls adipogenesis by coordinating the Wnt/beta-catenin signaling network.
Lagathu C; Christodoulides C; Virtue S; Cawthorn WP; Franzin C; Kimber WA; Nora ED; Campbell M; Medina-Gomez G; Cheyette BN; Vidal-Puig AJ; Sethi JK
Diabetes; 2009 Mar; 58(3):609-19. PubMed ID: 19073771
[TBL] [Abstract][Full Text] [Related]
8. Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer.
Kaltofen T; Preinfalk V; Schwertler S; Fraungruber P; Heidegger H; Vilsmaier T; Vattai A; Czogalla B; Mayr D; Mahner S; Jeschke U; Trillsch F
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2559-2574. PubMed ID: 32681294
[TBL] [Abstract][Full Text] [Related]
9. N
Fukumoto T; Zhu H; Nacarelli T; Karakashev S; Fatkhutdinov N; Wu S; Liu P; Kossenkov AV; Showe LC; Jean S; Zhang L; Zhang R
Cancer Res; 2019 Jun; 79(11):2812-2820. PubMed ID: 30967398
[TBL] [Abstract][Full Text] [Related]
10. Receptor for advanced glycation end product blockade enhances the chemotherapeutic effect of cisplatin in tongue squamous cell carcinoma by reducing autophagy and modulating the Wnt pathway.
Zhao Z; Wang H; Zhang L; Mei X; Hu J; Huang K
Anticancer Drugs; 2017 Feb; 28(2):187-196. PubMed ID: 27831944
[TBL] [Abstract][Full Text] [Related]
11. Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.
Zhang K; Song H; Yang P; Dai X; Li Y; Wang L; Du J; Pan K; Zhang T
Cell Prolif; 2015 Apr; 48(2):249-58. PubMed ID: 25643607
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells.
Gao Y; Liu Z; Zhang X; He J; Pan Y; Hao F; Xie L; Li Q; Qiu X; Wang E
Cancer Lett; 2013 Aug; 336(1):231-9. PubMed ID: 23673211
[TBL] [Abstract][Full Text] [Related]
13. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
14. USP43 impairs cisplatin sensitivity in epithelial ovarian cancer through HDAC2-dependent regulation of Wnt/β-catenin signaling pathway.
Pei L; Zhao F; Zhang Y
Apoptosis; 2024 Feb; 29(1-2):210-228. PubMed ID: 38087046
[TBL] [Abstract][Full Text] [Related]
15. TET1 inhibits EMT of ovarian cancer cells through activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2.
Duan H; Yan Z; Chen W; Wu Y; Han J; Guo H; Qiao J
Gynecol Oncol; 2017 Nov; 147(2):408-417. PubMed ID: 28851501
[TBL] [Abstract][Full Text] [Related]
16. Capn4 Enhances Osteopontin Expression through Activation of the Wnt/β-Catenin Pathway to Promote Epithelial Ovarian Carcinoma Metastasis.
Yang X; Sun J; Xia D; Can X; Liu L; Zhang J; Xu H; Du N; Liu W; Shen F; Zhang Z; Sun Y; Xi X
Cell Physiol Biochem; 2017; 42(1):185-197. PubMed ID: 28535511
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma.
Zhu J; Zhang S; Gu L; Di W
Carcinogenesis; 2012 Dec; 33(12):2334-43. PubMed ID: 22964660
[TBL] [Abstract][Full Text] [Related]
18. TGF-β signaling regulates DACT1 expression in intestinal epithelial cells.
Wang JL; Zhou X; Zhang LF; Li F; Wang BY; Wang WD; Fu W
Biomed Pharmacother; 2018 Jan; 97():864-869. PubMed ID: 29136762
[TBL] [Abstract][Full Text] [Related]
19. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
[TBL] [Abstract][Full Text] [Related]
20. Wnt/β-catenin signalling in ovarian cancer: Insights into its hyperactivation and function in tumorigenesis.
Nguyen VHL; Hough R; Bernaudo S; Peng C
J Ovarian Res; 2019 Dec; 12(1):122. PubMed ID: 31829231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
